

## Keliakia ja diabetes:

### Kohti yhteisiä seulontoja ja ennaltaehkäisyjä?

Kirjoittajat: ANNE EURÉN JA KALLE KURPPA

Julkaistu Diabetes ja lääkäri -lehdessä 14.2.2024

#### Kirjallisuus

1. Husby S, Koletzko S, Ilma Korponay-Szabó I, ym. European Society Paediatric Gastroenterology: Hepatology and nutrition guidelines for diagnosing coeliac disease 2020. *J Pediatr Gastroenterol Nutr* 2020;70:141-156.
2. Keliakia. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Kardiologisen Seuran asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2018. Saatavilla internetissä: [www.kaypahoito.fi](http://www.kaypahoito.fi)
3. Catassi C, Verdu EF, Bai JC, Lionetti E. Coeliac disease. *Lancet* 2022;399:2413-2426.
4. Lindfors K, Ciacci C, Kurppa K, ym. Coeliac disease. *Nat Rev Dis Primers* 2019;5:3.
5. Singh P, Arora A, Strand TA, ym. Global prevalence of celiac disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2018;16:823-836.
6. Kvamme J, Sørbye S, Florholmen J, Halstensen T. Population-based screening for celiac disease reveals that the majority of patients are undiagnosed and improve on a gluten-free diet. *Scientific Reports* 2022;12:12647.
7. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. *Lancet* 2016;387:2331-2339.
8. Sims EK, Besser REJ, Dayan C, ym. Screening for type 1 diabetes in the general population: a status report and perspective. *Diabetes* 2022;71:610-623.
9. Hekkala AM, Ilonen J, Toppari J, Knip M, Veijola R. Ketoacidosis at diagnosis of type 1 diabetes: Effect of prospective studies with newborn genetic screening and follow up of risk children. *Pediatr Diabetes* 2018;19:314-319.
10. Katsarou A, Gudbjörnsdóttir S, Rawshani A, ym. Type 1 diabetes mellitus. *Nat Rev Dis Primers* 2017;3:17016.
11. Jacobsen LM, Sherr JL, Considine E, ym. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. *Commun Med* 2023;3:132.
12. Insuliinipuutosdiabetes. Käypä hoito -suositus. Suomalaisen Lääkäriseuran Duodecimin, Suomen Sisätautilääkäreiden yhdistyksen ja Diabetesliiton Lääkärineuvoston asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2022 (viitattu 1.10.2023). Saatavilla internetissä: [www.kaypahoito.fi](http://www.kaypahoito.fi)
13. Gregory GA, Robinson TIG, Linklater SE, ym. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. *Lancet Diabetes Endocrinol* 2022;10:741-760.
14. Parviainen A, But A, Siljander H, Knip M. Decreased incidence of type 1 diabetes in young Finnish children. *Diabetes Care* 2020;43:2953-2958.
15. Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. *JAMA* 2013;310:427-428.
16. Fang M, Wang D, Echouffo-Tcheugui JB, Selvin E. Age at diagnosis in U.S. adults with type 1 diabetes. *Ann Intern Med* Doi: 10.7326/M23-1707.
17. Kurppa K, Laitinen A, Agardh D. Coeliac disease in children with type 1 diabetes. *Lancet Child Adolesc Health* 2018;2:133-143.

18. Hagopian W, Lee HS, Liu E, ym. Co-occurrence of type 1 diabetes and celiac disease autoimmunity. *Pediatrics* 2017;140:e20171305.
19. Kylökäs A, Kaukinen K, Huhtala H, ym. Type 1 and type 2 diabetes in celiac disease: prevalence and effect on clinical and histological presentation. *BMC Gastroenterol* 2016;16:76.
20. Tauschi R, Eurén A, Vuorela N, ym. Association of concomitant autoimmunity with the disease features and long-term treatment and health outcomes in Celiac disease. *Front Med* 2022;9:1055135.
21. Kivelä L, Kaukinen K, Lähdeaho ML, ym. Presentation of celiac disease in Finnish children is no longer changing: a 50-year perspective. *J Pediatr* 2015;167:1109-1115.
22. Lohi S, Mustalahti K, Kaukinen K, ym. Increasing prevalence of coeliac disease over time. *Aliment Pharmacol Ther* 2007;26:1217-1225.
23. Taavela J, Kurppa K, Jääskeläinen T, ym. Trends in the prevalence rates and predictive factors of coeliac disease: A long-term nationwide follow-up study. *Aliment Pharmacol Ther* Doi:10.1111/apt.17803.
24. Kondrashova A, Mustalahti K, Kaukinen K, ym. Lower economic status and inferior hygienic environment may protect against celiac disease. *Ann Med* 2008;40:223-231.
25. Kondrashova A, Reunanen A, Romanov A, ym. H. A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. *Ann Med* 2005;37:67-72.
26. Kempainen KM, Lynch KF, Liu E, ym. Factors That increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. *Clin Gastroenterol Hepatol* 2017;15:694-702.
27. Hyöty H, Hiltunen M, Lönnrot M. Enterovirus infections and insulin dependent diabetes mellitus--evidence for causality. *Clin Diagn Virol* 1998;9:77-84.
28. Oikarinen M, Puustinen L, Lehtonen J, ym. Enterovirus infections are associated with the development of celiac disease in a birth cohort study. *Front Immunol.* 2021;11:604529.
29. Lindfors K, Lin J, Lee HS, ym. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at-risk children: the TEDDY study. *Gut* 2020;69:1416-1422.
30. Myléus A, Hernell O, Gothefors L, ym. Early infections are associated with increased risk for celiac disease: an incident case-referent study. *BMC Pediatr* 2012;12:194.
31. Hakola L, Miettinen ME, Syrjälä E, ym. Association of cereal, gluten, and dietary fiber intake with islet autoimmunity and type 1 diabetes. *JAMA Pediatr* 2019;173:953-960.
32. Andrén Aronsson C, Lee HS, Hård Af Segerstad EM, ym. Association of gluten intake during the first 5 years of life with incidence of celiac disease autoimmunity and celiac disease among children at increased risk. *JAMA* 2019;322:514-523.
33. Kivelä L, Kurppa K. Screening for coeliac disease in children. *Acta Paediatr* 2018;107:1879-1887.
34. Kvamme JM, Sørbye S, Florholmen J, Halstensen TS. Population-based screening for celiac disease reveals that the majority of patients are undiagnosed and improve on a gluten-free diet. *Sci Rep* 2022;12:12647.
35. Sims EK, Besser REJ, Dayan C, ym. Screening for type 1 diabetes in the general population: a status report and perspective. *Diabetes* 2022;71:610-623.
36. Auricchio R, Mandile R, Del Vecchio MR, ym. Progression of celiac disease in children with antibodies against tissue transglutaminase and normal duodenal architecture. *Gastroenterology* 2019;157:413-420.

37. Popp A, Mäki M. Gluten-induced extra-intestinal manifestations in potential celiac disease-celiac trait. *Nutrients* 2019;11:320.
38. Kurppa K, Collin P, Viljamaa M, ym. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. *Gastroenterology* 2009;136:816-823.
39. Zanini B, Caselani F, Magni A, ym. Celiac disease with mild enteropathy is not mild disease. *Clin Gastroenterol Hepatol* 2013;11:253-258.
40. Repo M, Lindfors K, Mäki M, ym. Anemia and iron deficiency in children with potential celiac disease. *J Pediatr Gastroenterol Nutr* 2017;64:56-62.
41. Leffler D, Vanga R, Mukherjee R. Mild enteropathy celiac disease: a wolf in sheep's clothing? *Clin Gastroenterol Hepatol* 2013;11:259-261.
42. Husby S, Koletzko S, Korponay-Szabó I, ym. European Society Paediatric Gastroenterology, Hepatology and nutrition guidelines for diagnosing coeliac disease 2020. *J Pediatr Gastroenterol Nutr* 2020;70:141-156.
43. Schuppan D, Mäki M, Lundin KEA, ym. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. *N Engl J Med* 2021;385:35-45.
44. Kivelä L, Caminero A, Leffler DA, ym. Current and emerging therapies for coeliac disease. *Nat Rev Gastroenterol Hepatol* 2021;18:181-195.
45. Herold KC, Bundy BN, Long SA, ym. An Anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. *N Engl J Med* 2019;381:603-613.
46. Auricchio R, Troncone R. Can celiac disease be prevented? *Front Immunol* 2021;12:672148.
47. Uusitalo U, Liu X, Yang J, ym. Association of early exposure of probiotics and islet autoimmunity in the TEDDY Study. *JAMA Pediatr* 2016;170:20-28.
48. Uusitalo U, Andren Aronsson C, Liu X, ym. Early Probiotic supplementation and the risk of celiac disease in children at genetic risk. *Nutrients* 2019;11:1790.
49. Håkansson Å, Andrén Aronsson C, Brundin C, ym. Effects of *Lactobacillus plantarum* and *Lactobacillus paracasei* on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients* 2019;11:1925.
50. Oscarsson E, Håkansson Å, Andrén Aronsson C, Molin G, Agardh D. Effects of probiotic bacteria lactobacillaceae on the gut microbiota in children with celiac disease autoimmunity: a placebo-controlled and randomized clinical trial. *Front Nutr* 2021;8:680771.
51. Savilahti E, Härkönen T, Savilahti EM, Kukkonen K, Kuitunen M, Knip M. Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes. *Diabetologia* 2018;61:2668-2670.
52. Prevention of celiac disease in Skåne (PreCiSe). <https://clinicaltrials.gov/study/NCT03562221>.
53. Modulation of type 1 diabetes susceptibility through the use of probiotics. <https://clinicaltrials.gov/study/NCT03423589>
54. Prevention av autoimmunitet med laktobaciller (PAL). <https://clinicaltrials.gov/study/NCT04014660>).
55. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. *Diabetes Care* 2011;34:1301-1305.
56. Aronsson CA, Lee HS, Liu E, ym. Age at gluten introduction and risk of celiac disease. *Pediatrics* 2015;135:239-245.

57. Dunne JL, Richardson SJ, Atkinson MA, ym. Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. *Diabetologia* 2019;62:744-753.
58. Mameli C, Triolo TM, Chiarelli F, Rewers M, Zuccotti G, Simmons KM. Lessons and gaps in the prediction and prevention of type 1 diabetes. *Pharmacol Res* 2023;193:106792.